Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study

Summary

The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.

Timeline

Start

2026-12

Primary completion

2029-06

Completion

2029-07

Drugs

Indications